- Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, continue to pose significant global health challenges, driving demand for advanced diagnostics, therapeutics, and preventive solutions across both developed and developing regions
- The accelerating demand for infectious disease solutions is fueled by the increasing incidence of emerging and re-emerging infections, antimicrobial resistance, global travel, and aging populations with weakened immune responses
- North America dominated the infectious diseases market with the largest revenue share of 38.5% in 2024, characterized by robust healthcare infrastructure, high healthcare spending, and the presence of leading pharmaceutical and biotechnology companies actively engaged in vaccine and drug development
- Asia-Pacific is expected to be the fastest growing region in the infectious diseases market during the forecast period due to rising investments in healthcare infrastructure, government-led immunization initiatives, and a growing patient population susceptible to infectious outbreaks
- Polymerase Chain Reaction (PCR), segment dominated the infectious diseases market with a market share of 35.4% in 2024, driven by its high sensitivity, rapid turnaround time, and broad applicability in detecting a wide range of pathogens accurately
